Medication-Assisted Treatment - Prescription Drug and Opioid Addiction

The Medication-Assisted Treatment - Prescription Drug and Opioid Addiction (MAT-PDOA) program is a grant initiative administered by the Substance Abuse and Mental Health Services Administration (SAMHSA), a division of the U.S. Department of Health and Human Services. This funding opportunity aims to combat the ongoing opioid crisis in the United States by expanding access to medications for opioid use disorder (MOUD). The initiative aligns with national strategies to reduce overdose deaths, curb the misuse of prescription opioids, and provide comprehensive support for individuals affected by opioid use disorder. As forecasted under the opportunity number TI-26-008, the MAT-PDOA program seeks to increase the availability and utilization of evidence-based treatment options across the country. Specifically, the grant supports the implementation and enhancement of medication-assisted treatment services, enabling more providers to deliver integrated care that combines FDA-approved medications with counseling and behavioral therapies. The overarching objective is to improve treatment access, retention, and outcomes for individuals struggling with opioid addiction. The MAT-PDOA funding opportunity is open to domestic public and private nonprofit entities, including faith-based organizations. This broad eligibility reflects SAMHSA’s commitment to engaging a wide range of community-based stakeholders to address the opioid epidemic. While the specific eligibility requirements emphasize nonprofit status, the flexibility in organizational types allows for a diverse cohort of grantees, each positioned to address the needs of their unique service populations. There are no stated geographic restrictions, suggesting the program is nationwide in scope. According to the forecast, SAMHSA expects to fund approximately 90 awards under this initiative, with a total anticipated program funding level of $67.5 million. However, as this is a forecasted opportunity, specific details such as the award ceiling and floor, project period duration, and precise allowable expenses have not yet been published. Applicants will need to consult the final Notice of Funding Opportunity (NOFO) when released for definitive guidance on the use of funds, reporting requirements, and cost restrictions. The expected release date for the full application guidelines is May 15, 2026. Although the estimated application due date has not been posted, this timeline suggests an application window likely during late spring or summer 2026. As of the forecast’s latest update on March 20, 2026, no pre-application steps such as Letters of Intent or Concept Papers have been indicated, and there is no suggestion of a required matching contribution. Interested applicants should monitor SAMHSA's website and Grants.gov for updates. Inquiries related to the MAT-PDOA program can be directed to Fred Bamfo at 240-276-2423 or via email at [email protected]. Because this is a forecasted opportunity, organizations are encouraged to engage in early planning and capacity-building activities to ensure readiness when the application window opens. Continued review of SAMHSA’s site and Grants.gov is recommended for the release of the official NOFO and any supplemental application instructions or webinars that may follow.